Meeder Advisory Services Inc. Buys New Shares in Moderna, Inc. $MRNA

Meeder Advisory Services Inc. purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 7,734 shares of the company's stock, valued at approximately $542,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of MRNA. Allied Private Wealth LLC bought a new stake in shares of Moderna in the 2nd quarter worth approximately $30,000. Canton Hathaway LLC bought a new position in shares of Moderna during the 1st quarter valued at $31,000. Assetmark Inc. grew its holdings in shares of Moderna by 35.1% during the 1st quarter. Assetmark Inc. now owns 801 shares of the company's stock valued at $41,000 after purchasing an additional 208 shares during the last quarter. Strategic Investment Solutions Inc. IL purchased a new position in Moderna in the 2nd quarter worth $61,000. Finally, MUFG Securities EMEA plc purchased a new position in Moderna in the 2nd quarter worth $28,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, President Stephen Hoge sold 53,336 shares of the firm's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president owned 1,483,848 shares of the company's stock, valued at $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the sale, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 10.80% of the company's stock.

Analyst Ratings Changes

MRNA has been the subject of several analyst reports. The Goldman Sachs Group upped their price target on shares of Moderna from $67.00 to $120.00 and gave the company a "neutral" rating in a research report on Wednesday. Citigroup lifted their price objective on Moderna from $41.00 to $60.00 and gave the stock a "neutral" rating in a report on Monday, August 3rd. William Blair raised Moderna from a "market perform" rating to an "outperform" rating in a research note on Wednesday. Jefferies Financial Group restated a "hold" rating on shares of Moderna in a report on Wednesday. Finally, Wolfe Research restated an "underperform" rating and set a $25.00 price target on shares of Moderna in a research report on Monday, July 20th. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $66.25.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Phase 3 melanoma success validates Moderna’s mRNA platform. Moderna and Merck said their personalized cancer vaccine, intismeran autogene, combined with Keytruda, met both recurrence-free-survival and distant-metastasis-free-survival endpoints in high-risk, fully resected Stage IIB-IV melanoma patients. The result is described as the first positive late-stage trial for a personalized mRNA cancer vaccine and could support regulatory filings as early as 2027. Merck and Moderna Phase 3 trial announcement
• Positive Sentiment: Investors see potential beyond COVID-19 vaccines. Analysts believe a successful personalized oncology product could establish a major new revenue stream and raise the value of Moderna’s broader cancer pipeline, including programs targeting lung, kidney and bladder cancers. Jefferies estimated potential global peak sales of approximately $54 billion and raised its price target to $170, while other estimates were more conservative. Moderna oncology platform draws Street value
• Neutral Sentiment: The sharp move was amplified by a short squeeze. Reports estimate that short sellers faced billions of dollars in mark-to-market losses after the trial news, forcing some to buy shares to cover positions. This technical support can intensify gains but may not represent sustained fundamental demand. Moderna short-sellers report
• Negative Sentiment: Profit-taking and valuation concerns are driving the pullback. The stock’s earlier surge priced in substantial success, and several analysts’ revised targets remained below the prevailing market price. Morgan Stanley raised its target but maintained an equal-weight rating, citing limited near-term upside. Moderna valuation concerns
• Negative Sentiment: Important risks remain. Moderna has released topline results, but investors are awaiting detailed data, regulatory review and eventual commercialization. Doctors and analysts have also cautioned that enthusiasm may be running ahead of the evidence, leaving the shares vulnerable to further volatility. Moderna personalized mRNA shot analysis

Moderna Stock Down 23.5%

NASDAQ MRNA opened at $133.32 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The stock has a market capitalization of $53.23 billion, a PE ratio of -16.69 and a beta of 0.91. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $176.66. The business's 50-day moving average is $66.58 and its 200 day moving average is $55.47.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating analysts' consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.Moderna's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.13) EPS. Sell-side analysts forecast that Moderna, Inc. will post -6.18 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source